Hostname: page-component-586b7cd67f-rdxmf Total loading time: 0 Render date: 2024-11-23T22:09:25.951Z Has data issue: false hasContentIssue false
  • English
  • Français

Dibenzepin and Amitriptyline in the Treatment of Depression

Published online by Cambridge University Press:  29 January 2018

M. Y. Ekdawi
M. Y. Ekdawi*
Affiliation:
Netherne Hospital, Coulsdon, Surrey
Get access Rights & Permissions [Opens in a new window]

Extract

Dibenzepin hydrochloride is a new tricyclic antidepressant drug with pharmacological properties midway between those of imipramine and amitriptyline. In a double-blind comparative trial, J. M. Fielding (Med. J. Australia, 1969, 1, 614) found no significant difference in the speed of the effect of the two drugs in depressed patients. He reported that side-effects rated subjectively by patients were maximal before starting on the drugs and tended to decrease with time. The following trial was accordingly staged.

Type
Abstract
Information
The British Journal of Psychiatry , Volume 118 , Issue 546 , May 1971 , pp. 523 - 524
Copyright
Copyright © Royal College of Psychiatrists, 1971 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

eLetters

No eLetters have been published for this article.